Microtao biotech completed a pre-Series A financing round of over 100 million yuan.

Recently, the innovative company in the field of global cell therapy, MicroTao Biotechnology Co., Ltd, announced the completion of a round of financing of over 100 million RMB. This round of financing was led by Sequoia Capital and the funds will mainly be used for the iterative optimization of the core technology platform and the clinical transformation and development of the first candidate product in the field of autoimmune diseases.